SCHEMBL49609

SCHEMBL49609

COc1ccc(P)c(-c2ccccc2)c1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.44
FABP4 P15090 1/20 0.44
FABP5 Q01469 1/20 0.44
KMT2A Q03164 5/20 0.44
MAPT P10636 4/20 0.44
MEN1 O00255 4/20 0.44
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 3/20 0.44
USP2 O75604 2/20 0.44
DUSP3 P51452 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
PDE4B Q07343 3/20 0.42
PDE4A P27815 2/20 0.42
PDE4C Q08493 2/20 0.42
PDE4D Q08499 2/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA7 P43166 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28572577 0.91 FABP3 (0.39) FABP3FABP4FABP5KMT2AMAPT
SCHEMBL27876715 0.86 PDE4B (0.47) FABP3FABP4FABP5KMT2AMAPT
SCHEMBL4349595 0.84 FABP3 (0.43) FABP3FABP4FABP5KMT2AMAPT
SCHEMBL366231 0.83 FABP3 (0.44) FABP3FABP4FABP5KMT2AMAPT
SCHEMBL6130251 0.81 PDE4B (0.42) FABP3FABP4FABP5ALDH1A1KDM4E
SCHEMBL26259629 0.78 MAPT (0.52) FABP3FABP4FABP5KMT2AMAPT
SCHEMBL355567 0.78 CA1 (0.57) FABP3FABP4FABP5KMT2AMAPT
SCHEMBL6263322 0.78 ALDH1A1 (0.56) FABP3FABP4FABP5KMT2AMAPT
SCHEMBL6545302 0.78 FABP3 (0.43) FABP3FABP4FABP5KMT2AMAPT
SCHEMBL8329781 0.78 PDE4B (0.50) FABP3FABP4FABP5KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129467-B2 Curing accelerating compound-silica composite material, method for producing curing accelerating compound-silica composite material, curing accelerator, curable resin composition, and electronic component device HITACHI CHEMICAL CO., LTD. (JP) 2012-03-06 US disclosed
US-20090062460-A1 CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, METHOD FOR PRODUCING CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, CURING ACCELERATOR, CURABLE RESIN COMPOSITION, AND ELECTRONIC COMPONENT DEVICE HITACHI CHEMICAL CO., LTD. (JP) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062460-A1 CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, METHOD FOR PRODUCING CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, CURING ACCELERATOR, CURABLE RESIN COMPOSITION, AND ELECTRONIC COMPONENT DEVICE NCAPH, RAD51, H1-2 FABP3 4811/4885FABP4 4594/4885FABP5 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.